Many Businesses have changed their working practices as a result of COVID-19. For example, GlaxoSmithKline is shrinking its office footprint in the United States by moving to new sites, adapting to how work is done these days. GSK is downsizing its North Carolina and Philadelphia operations in favor of smaller locations in the same areas. After nearly 40 years as a resident of Research Triangle Park (RTP), GSK will vacate its 562,000 square-foot sites.
The British pharmaceutical company downsizes and relocates to the American Tobacco Campus in downtown Durham, North Carolina, with 68,000 square feet of offices. The relocation also includes the headquarters of GSK’s HIV-focused joint venture ViiV Healthcare in the United States. At the same time, GSK plans to relocate its Philadelphia headquarters from the 207,780-square-foot Navy Yard property to the FMC Tower in University City, which will house around 50,000 square feet of additional offices.
During the pandemic, biopharma Businesses have altered their working patterns to a hybrid of in-person and remote labor. Novartis CEO Vas Narasimhan stated in an interview with Bloomberg in April that he expected the combination of in-office and at-home labor to continue beyond the pandemic.